5 New Diabetes Technologies and Treatments

Two posted presented at the American Heart Association’s 2024 Scientific Sessions explored empagliflozin among patients with type 2 diabetes and cardiovascular risk.

Don Arthur, RPh, discusses what lays ahead in independent pharmacy, from clinical care to success stories.

A study found that a continuous glucose monitor workflow led by a pharmacist led to reduced HbA1c levels.

Lani Bertrand, RPh, joins the latest episode of Over The Counter to discuss the role of technology in easing burnout during the COVID-19 pandemic.

Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses a recent meta-analysis that evaluated the efficacy, safety, and clinical implications of insulin icodec.

A recent study found the percentage of type 1 diabetes patients who were prescribed either GLP-1s or SGLT2 inhibitors increased from 0.7% to 8.3% between 2010 and 2023.